Skip to content


Letairis, Volibris (ambrisentan) is a small molecule pharmaceutical. Ambrisentan was first approved as Letairis on 2007-06-15. It is used to treat pulmonary hypertension in the USA. It has been approved in Europe to treat pulmonary hypertension. The pharmaceutical is active against endothelin-1 receptor. In addition, it is known to target endothelin receptor type B. Letairis's patents are valid until 2031-10-14 (FDA).
Trade Name Volibris
Common Name Ambrisentan
Indication pulmonary hypertension
Drug Class Endothelin receptor antagonists
Get full access now